Cigna is trading 5.34% lower in pre-market at $290.57, with no new company announcement or earnings release reported for October 26. - Shares closed at $306.95 on October 23. - A House investigation announced October 23 includes Express Scripts, Cigna’s pharmacy benefit manager; reporting does not establish it as the cause of the decline. - Third-quarter results are scheduled for November 5; broader market indicators are mixed and do not clearly explain the move.